Posted by Michael Wonder on 17 Oct 2018
Lojuxta to be reimbursed in France
17 October 2018 - Amryt's lead commercial product now available in all five of the EU's largest markets
Amryt Pharma is pleased to announce that it has reached agreement with France's CEPS (Comité économique des produits de santé), to reimburse Lojuxta (lomitapide) for the treatment of adult patients with homozygous familial hypercholesterolaemia in France.
This approval now means that Lojuxta is available across all five of the EU's major markets (France, the UK, Italy, Germany and Spain), either by responding to named patient requests or on a fully reimbursed basis and is in line with Amryt's strategy to make Lojuxta available to more patients across Amryt's licensed territories.
